[267] In another randomized study published in 2003 (Meneilly et al.), 16 elderly, insulin-nave patients with diabetes were divided in two groups of 8 patients each, and given either a continuous subcutaneous infusion of GLP-1 at an initial dose of 100 pmol/kg/h, titrated up to a maximum dose of 120 pmol/kg/h for 12 weeks, compared to controls treated with conventional therapy
While tirzepatide is a gold-standard diabetes treatment right now, retatrutides multi-pathway profile suggests it could offer an equally powerful, if not uniquely specialized, alternative for severe insulin resistance and advanced metabolic syndrome once approved
Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, et al
Although the expression of GLP-1R in liver tissue is controversial, GLP-1RAs have been shown to act as regulatory pathways affecting metabolic disorders
When inflammation is the baseline rather than a short event, KLOW is the cleaner fit